小儿湿疹局部用中药新药临床试验设计与评价技术指南

Guideline on evaluation of Chinese medical research for treatment of eczema in children

《儿科常见疾病中药新药临床试验设计与评价技术指南》是中华中医药学会儿科分会临床评价学组制定的、指导儿科中药Ⅱ期、Ⅲ期临床试验和上市后有效性再评价方案设计的、具有病种特色的系列临床评价技术指南,旨在推动儿科中药临床试验设计与评价水平的提高,并为临床提供安全有效的儿童用药。采用世界卫生组织(WHO)推荐的"共识会议法"和美国国立卫生研究院(NIH)发展共识方案(GPP)有关原则,国内全部18 个国家药物临床试验机构中医儿科专业的临床儿科专家以及国内相关临床评价专家参加了急性上呼吸道感染、急性支气管炎、支气管哮喘、反复呼吸道感染、厌食、轮状病毒性肠炎、注意缺陷–多动障碍、抽动障碍、遗尿症、手足口病、湿疹11 个儿科常见病种指南的起草或多次提出修改建议,历经3 年反复完善,最终形成共识,并由中华中医药学会儿科分会于2013 年10 月发布。本指南从研究背景、研究目标、总体设计、诊断标准、受试者的选择、给药方案、安全性评价、有效性评价、试验流程、数据管理与统计分析、质量保证、相关伦理学要求、试验结束后的医疗措施、资料保存等方面阐述了小儿湿疹中药新药临床试验的设计与评价技术要点,期望能为申办者与研究者在临床试验方案设计中提供指导。

The series of Guideline on evaluation of Chinese medical research for treatment of common disease in children were issued by Clinical Evaluation Unit, Pediatric Branch of China Association for Traditional Chinese Medicine. It is developed to assist applicants during the development and re-evaluation of pediatric medicine, in order to provide safer and better medicines for children.The guidelines were developed by all 18 clinical trial institutions of traditional Chinese medicine (TCM), utilized the 'consensus meeting method', which was recommended by WHO, and the consensus development program (GPP) principles of National Institutes of Health (NIH). It involved phases II and III to post marketing re-evaluation in 11 kinds of pediatric diseases, such as acute upper respiratory infection, acute bronchitis, bronchial asthma, recurrent respiratory tract infections (RRTI), anorexia, rotavirus gastroenteritis, attention-deficit/hyperactivity disorder, tic disorders, enuresis, hand-foot-and-mouth disease, and eczema. It spent three years form the first draft to the last version, and after repeated revise, it was eventually released by CACM in October 2013. This Eczema Guideline intends to address the position in the main topics of clinical development of new Chinese medicinal products in the treatment of eczema in children. The elaboration included possible claims, clinical study design, selection of patients, endpoints, safety observation, as well as other significant points. It aims at providing the possible guidance for sponsor and investigators of clinical trial.